Semin Thromb Hemost 2023; 49(01): 003-008
Maintaining Hemostasis and Preventing Thrombosis in Coronavirus Disease 2019 (COVID-19)—Part
IV
1
Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute
of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia
,
1
Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute
of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, Australia
,
2
Section of Clinical Biochemistry and School of Medicine, University of Verona, Verona,
Italy
› Author Affiliations
References
1
Favaloro EJ,
Lippi G.
Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part
I. Semin Thromb Hemost 2020; 46 (07) 757-762 2
Favaloro EJ,
Lippi G.
Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19):
part II. Semin Thromb Hemost 2021; 47 (04) 333-337 3
Favaloro EJ,
Lippi G.
Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part
III. Semin Thromb Hemost 2022; 48 (01) 3-7 4
COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns
Hopkins University.
(JHU). Accessed November 2, 2022 at: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 5
Tregoning JS,
Flight KE,
Higham SL,
Wang Z,
Pierce BF.
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy,
effectiveness and escape. Nat Rev Immunol 2021; 21 (10) 626-636 6
Sharma K,
Koirala A,
Nicolopoulos K,
Chiu C,
Wood N,
Britton PN.
Vaccines for COVID-19: where do we stand in 2021?. Paediatr Respir Rev 2021; 39: 22-31
7
Raman R,
Patel KJ,
Ranjan K.
COVID-19: unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies.
Biomolecules 2021; 11 (07) 993 8 COVID-19 vaccines. Accessed November 2, 2022 at: https://en.wikipedia.org/wiki/COVID-19_vaccine 9
Lippi G,
Favaloro EJ.
Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VAT, TTS and
more. Semin Thromb Hemost 2022; 48 (01) 8-14 10
Zidan A,
Noureldin A,
Kumar SA,
Elsebaie A,
Othman M.
COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic
discrepancies and global implications. Semin Thromb Hemost 2023; 49 (01) 9-14 11
Favaloro EJ.
Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia.
Int J Lab Hematol 2021; 43 (04) 559-570 12
Favaloro EJ,
Pasalic L,
Lippi G.
Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic
thrombocytopenia (VITT). Clin Chem Lab Med 2021; 60 (01) 7-17 13
Franchini M,
Cappello E,
Valdiserra G.
et al.
Investigating a signal of acquired haemophilia associated with COVID-19 vaccination:
a systematic case review. Semin Thromb Hemost 2023; 49 (01) 15-26 14
Lippi G,
Favaloro EJ.
What we know (and don't know) regarding the pathogenesis of pulmonary thrombosis in
COVID-19. Semin Thromb Hemost 2023; 49 (01) 27-33 15
Buso G,
Mazzolai L,
Rueda-Camino JA.
et al.
RIETE Investigators.
Pulmonary embolism in patients with COVID-19: comparison between different care settings.
Semin Thromb Hemost 2023; 49 (01) 36-46 16
Candeloro M,
Schulman S.
Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis.
Semin Thromb Hemost 2023; 49 (01) 47-54 17
Iba T,
Wada H,
Levy JH.
Platelet activation and thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01)
55-61 18
Rizk JG,
Gupta A,
Lazo JG.
et al.
To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 years. Semin
Thromb Hemost 2023; 49 (01) 62-72 19
Lippi G,
Henry BM,
Favaloro EJ.
The benefits of heparin use in COVID-19: pleiotropic antiviral activity beyond anticoagulant
and anti-inflammatory properties. Semin Thromb Hemost 2023; 49 (01) 73-75 20
Cuker A.
The case for therapeutic-intensity anticoagulation in patients with COVID-19-associated
moderate illness. Semin Thromb Hemost 2023; 49 (01) 76-78 21
Rizk JG,
Lavie CJ,
Henry BM.
Against therapeutic anticoagulation in critically ill COVID-19 patients. Semin Thromb
Hemost 2023; 49 (01) 79-80 22
Lippi G,
Favaloro EJ.
Strength of anticoagulation in moderate to severe COVID-19 illness: in medio stat
virtus?. Semin Thromb Hemost 2023; 49 (01) 81-84 23
Rizk JG,
Lazo JG,
Gupta A,
Lavie CJ,
Effron MB.
Proposal for a simple algorithmic approach to manage drug-drug interactions with oral
anticoagulants and nirmatrelvir/ritonavir in COVID-19 outpatients. Semin Thromb Hemost
2023; 49 (01) 85-88 24
Tso ACY,
Ong KH,
Sum CLL.
et al.
Acquired thrombotic thrombocytopenic purpura (aTTP): a rare coincidence after COVID-19
mRNA vaccine?. Semin Thromb Hemost 2023; 49 (01) 89-91 25
Zaid Y,
Lahlimi Q,
Khalki L.
et al.
Aspirin use reduces platelet hyper-reactivity and degranulation in COVID-19 patients.
Semin Thromb Hemost 2023; 49 (01) 92-96 26
Arcani R,
Cauchois R,
Suchon P.
et al.
“True” antiphospholipid syndrome in COVID-19: contribution of the follow-up of antiphospholipid
autoantibodies. Semin Thromb Hemost 2023; 49 (01) 97-102 27
Carnevale S,
Giovanetti M,
Benvenuto D,
Ciccozzi M,
Broccolo F.
Is molecular mimicry between hPF4 and SARS-CoV-2 Spike protein a potential basis for
autoimmune responses in vaccinated and naturally infected patients?. Semin Thromb
Hemost 2023; 49 (01) 103-104 28
Mungmunpuntipantip R,
Wiwanitkit V.
Molecular mimicry between hPF4 and SARS-CoV-2 spike protein. Comment. Semin Thromb
Hemost 2023; 49 (01) 105 29
Benvenuto D,
Carnevale S,
Giovanetti M,
Ciccozzi M,
Broccolo F.
Molecular mimicry between hPF4 and SARS-CoV-2 spike protein: response to comment.
Semin Thromb Hemost 2023; 49 (01) 106-107 30
Favaloro EJ,
Henry BM,
Lippi G.
Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of
the literature. Semin Thromb Hemost 2022; 48 (01) 55-71 31
Favaloro EJ,
Henry BM,
Lippi G.
COVID-19 and antiphospholipid antibodies: time for a reality check?. Semin Thromb
Hemost 2022; 48 (01) 72-92
